.svg)
Digital asset management for pharmaceuticals is DAM built for the industry's regulated content — promotional and medical materials, scientific imagery and video, brand assets, and congress and field content — with MLR (medical, legal, regulatory) approval workflows, version and rights control, and audit trails that satisfy both marketing governance and regulatory scrutiny.
Pharma promotional content cannot be used until it passes medical, legal, and regulatory review — a controlled, documented, multi-reviewer approval that a pharma DAM must enforce natively. Only approved, in-date, market-appropriate versions may reach field teams and channels; expired or unapproved materials must be blocked. The system tracks which claims are substantiated, which markets a piece is cleared for, and the full approval history for every asset — an audit artifact, not a convenience.
Pharma operates across markets with different regulatory requirements, so the same asset may be approved for one country and prohibited in another — the DAM must enforce market-level rights and expiry. Alongside promotional material, it manages scientific and medical imagery, congress content, and training media, applying consistent version control and access governance. Data-handling and residency requirements often push deployment toward private-cloud or on-premises models.
ioMoVo delivers pharma-grade DAM — MLR approval workflows, market-level rights and expiry, audit trails, and scientific-media handling — with deployment options that meet pharma data-residency requirements. See the ioMoVo life sciences page.
Because promotional content requires enforced MLR approval, market-level rights control, and audit trails that general-purpose DAM does not provide out of the box.
It creates regulatory and legal exposure — which is why a pharma DAM blocks unapproved or expired assets from reaching field teams and channels.